Delayed
Toronto S.E.
17:31:26 16/05/2024 BST
|
5-day change
|
1st Jan Change
|
0.02
CAD
|
0.00%
|
|
0.00%
|
-20.00%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
15.12
|
5.4
|
6.75
|
4.32
|
1.62
|
1.35
|
Enterprise Value (EV)
1 |
12.18
|
3.923
|
6.08
|
4.424
|
2.188
|
2.899
|
P/E ratio
|
-10.6
x
|
-4.45
x
|
-9.56
x
|
-5.42
x
|
-2.44
x
|
-0.61
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
67.7
x
|
4.67
x
|
4.91
x
|
2.46
x
|
1.3
x
|
3.28
x
|
EV / Revenue
|
54.5
x
|
3.39
x
|
4.42
x
|
2.52
x
|
1.75
x
|
7.03
x
|
EV / EBITDA
|
-
|
-
|
-8,667,318
x
|
-5,831,652
x
|
-2,641,087
x
|
-3,016,912
x
|
EV / FCF
|
-29.7
x
|
-3.47
x
|
-12.1
x
|
-7.92
x
|
-5.01
x
|
-3.62
x
|
FCF Yield
|
-3.37%
|
-28.8%
|
-8.23%
|
-12.6%
|
-20%
|
-27.6%
|
Price to Book
|
3.81
x
|
1.9
x
|
3.3
x
|
2.41
x
|
1.48
x
|
-1.19
x
|
Nbr of stocks (in thousands)
|
54,000
|
54,000
|
54,000
|
54,000
|
54,000
|
54,000
|
Reference price
2 |
0.2800
|
0.1000
|
0.1250
|
0.0800
|
0.0300
|
0.0250
|
Announcement Date
|
29/04/19
|
13/05/20
|
26/04/21
|
29/04/22
|
27/04/23
|
29/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.2234
|
1.157
|
1.375
|
1.753
|
1.247
|
0.4121
|
EBITDA
|
-
|
-
|
-0.7014
|
-0.7587
|
-0.8284
|
-0.9609
|
EBIT
1 |
-1.485
|
-1.414
|
-0.7096
|
-0.7868
|
-0.9361
|
-1.283
|
Operating Margin
|
-664.6%
|
-122.15%
|
-51.6%
|
-44.89%
|
-75.08%
|
-311.3%
|
Earnings before Tax (EBT)
1 |
-1.421
|
-1.215
|
-0.7058
|
-0.7965
|
-0.6641
|
-2.224
|
Net income
1 |
-1.421
|
-1.215
|
-0.7058
|
-0.7965
|
-0.6641
|
-2.224
|
Net margin
|
-635.95%
|
-104.97%
|
-51.32%
|
-45.44%
|
-53.26%
|
-539.7%
|
EPS
2 |
-0.0263
|
-0.0225
|
-0.0131
|
-0.0148
|
-0.0123
|
-0.0412
|
Free Cash Flow
1 |
-0.41
|
-1.131
|
-0.5006
|
-0.5583
|
-0.4366
|
-0.8003
|
FCF margin
|
-183.51%
|
-97.7%
|
-36.4%
|
-31.85%
|
-35.02%
|
-194.21%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
29/04/19
|
13/05/20
|
26/04/21
|
29/04/22
|
27/04/23
|
29/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
0.1
|
0.57
|
1.55
|
Net Cash position
1 |
2.94
|
1.48
|
0.67
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-0.1374
x
|
-0.6856
x
|
-1.612
x
|
Free Cash Flow
1 |
-0.41
|
-1.13
|
-0.5
|
-0.56
|
-0.44
|
-0.8
|
ROE (net income / shareholders' equity)
|
-31.5%
|
-35.6%
|
-28.9%
|
-41.6%
|
-46.1%
|
9,743%
|
ROA (Net income/ Total Assets)
|
-15.6%
|
-18.3%
|
-11.2%
|
-13.7%
|
-18.4%
|
-44.1%
|
Assets
1 |
9.105
|
6.62
|
6.274
|
5.811
|
3.616
|
5.048
|
Book Value Per Share
2 |
0.0700
|
0.0500
|
0.0400
|
0.0300
|
0.0200
|
-0.0200
|
Cash Flow per Share
2 |
0.0500
|
0.0300
|
0.0100
|
0
|
0
|
0
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
29/04/19
|
13/05/20
|
26/04/21
|
29/04/22
|
27/04/23
|
29/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -20.00% | 792K | | +9.74% | 118B | | +10.77% | 106B | | -10.94% | 23.4B | | -1.69% | 22.1B | | -10.23% | 18.34B | | -41.92% | 16.59B | | -15.30% | 15.97B | | +6.56% | 14.03B | | +17.26% | 11.67B |
Bio Therapeutic Drugs
|